
Validea's guru fundamental report assigns Amgen (AMGN), a large-cap growth stock in the Biotechnology & Drugs sector, an 81% rating using its Multi-Factor Investor model, based on Pim van Vliet's strategy. This model prioritizes low volatility stocks that also exhibit strong momentum and high net payout yields, with the 81% score indicating Validea's 'some interest' in AMGN's underlying fundamentals and valuation.
Amgen, Inc. (AMGN) receives a moderately positive rating of 81% from Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy targeting low-volatility stocks with strong momentum and high yields. This score signifies 'some interest' in the stock based on its fundamentals and valuation. Delving into the specific criteria, AMGN successfully passes the model's screens for market capitalization and standard deviation, confirming its profile as a large-cap, low-volatility security. However, its performance is less compelling on other key factors, receiving a 'Neutral' score for both its 'Twelve Minus One Momentum' and its 'Net Payout Yield'. Critically, despite the positive attributes, the report notes that AMGN ultimately receives a 'FAIL' on the 'FINAL RANK' criterion, indicating that while it possesses the desired low-risk characteristics, it currently lacks the requisite strength in momentum and shareholder returns to fully align with the strategy's formula for outperformance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment